Research programme: cancer therapeutics - Cancer Therapeutics CRC/Novation Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Cancer Therapeutics CRC/Novation Pharmaceuticals

Latest Information Update: 05 Mar 2014

Price : $50

At a glance

  • Originator Cancer Therapeutics CRC
  • Developer Cancer Therapeutics CRC; Novation Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Mar 2014 Discontinued for Cancer in Canada (unspecified route)
  • 05 Mar 2014 Discontinued for Cancer in Australia (unspecified route)
  • 15 Jun 2009 Early research in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top